FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309551491> ?p ?o ?g. }

• W4309551491 endingPage "616" @default.
• W4309551491 startingPage "605" @default.
• W4309551491 abstract "Given the limited options and often harmful side effects of current analgesics and the suffering caused by the opioid crisis, new classes of pain therapeutics are needed. Protease-activated receptors (PARs), particularly PAR2, are implicated in a variety of pathologies, including pain. Since the discovery of the role of PAR2 in pain, development of potent and specific antagonists has been slow. In this study, we describe the in vivo characterization of a novel small molecule/peptidomimetic hybrid compound, C781, as a β-arrestin-biased PAR2 antagonist. In vivo behavioral studies were done in mice using von Frey filaments and the Mouse Grimace Scale. Pharmacokinetic studies were done to assess pharmacokinetic/pharmacodynamic relationship in vivo. We used both prevention and reversal paradigms with protease treatment to determine whether C781 could attenuate protease-evoked pain. C781 effectively prevented and reversed mechanical and spontaneous nociceptive behaviors in response to small molecule PAR2 agonists, mast cell activators, and neutrophil elastase. The ED50 of C781 (intraperitoneal dosing) for inhibition of PAR2 agonist (20.9 ng 2-AT)-evoked nociception was 6.3 mg/kg. C781 was not efficacious in the carrageenan inflammation model. Pharmacokinetic studies indicated limited long-term systemic bioavailability for C781 suggesting that optimizing pharmacokinetic properties could improve in vivo efficacy. Our work demonstrates in vivo efficacy of a biased PAR2 antagonist that selectively inhibits β-arrestin/MAPK signaling downstream of PAR2. Given the importance of this signaling pathway in PAR2-evoked nociception, C781 exemplifies a key pharmacophore for PAR2 that can be optimized for clinical development. PERSPECTIVE: Our work provides evidence that PAR2 antagonists that only block certain aspects of signaling by the receptor can be effective for blocking protease-evoked pain in mice. This is important because it creates a rationale for developing safer PAR2-targeting approaches for pain treatment." @default.
• W4309551491 created "2022-11-28" @default.
• W4309551491 creator A5001243278 @default.
• W4309551491 creator A5012818050 @default.
• W4309551491 creator A5024187988 @default.
• W4309551491 creator A5035762137 @default.
• W4309551491 creator A5037411659 @default.
• W4309551491 creator A5040294572 @default.
• W4309551491 creator A5060694758 @default.
• W4309551491 creator A5077315361 @default.
• W4309551491 creator A5079356211 @default.
• W4309551491 date "2023-04-01" @default.
• W4309551491 modified "2023-09-26" @default.
• W4309551491 title "C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice" @default.
• W4309551491 cites W1006559644 @default.
• W4309551491 cites W142954314 @default.
• W4309551491 cites W1479971025 @default.
• W4309551491 cites W155972599 @default.
• W4309551491 cites W1575211640 @default.
• W4309551491 cites W1593555249 @default.
• W4309551491 cites W1599631170 @default.
• W4309551491 cites W1827703464 @default.
• W4309551491 cites W1889671843 @default.
• W4309551491 cites W193867833 @default.
• W4309551491 cites W1955447442 @default.
• W4309551491 cites W1966538694 @default.
• W4309551491 cites W1970652854 @default.
• W4309551491 cites W1982881083 @default.
• W4309551491 cites W1990079562 @default.
• W4309551491 cites W1997958887 @default.
• W4309551491 cites W2001538429 @default.
• W4309551491 cites W2001893139 @default.
• W4309551491 cites W2012747631 @default.
• W4309551491 cites W2020098484 @default.
• W4309551491 cites W2036267752 @default.
• W4309551491 cites W2040585289 @default.
• W4309551491 cites W2040642697 @default.
• W4309551491 cites W2042317275 @default.
• W4309551491 cites W2047273197 @default.
• W4309551491 cites W2054399649 @default.
• W4309551491 cites W2056362028 @default.
• W4309551491 cites W2056781391 @default.
• W4309551491 cites W2061827338 @default.
• W4309551491 cites W2071342874 @default.
• W4309551491 cites W2083964238 @default.
• W4309551491 cites W2085176272 @default.
• W4309551491 cites W2102163179 @default.
• W4309551491 cites W2114622644 @default.
• W4309551491 cites W2129559551 @default.
• W4309551491 cites W2135982053 @default.
• W4309551491 cites W2159164710 @default.
• W4309551491 cites W2167067772 @default.
• W4309551491 cites W2172201406 @default.
• W4309551491 cites W2330592952 @default.
• W4309551491 cites W2345324041 @default.
• W4309551491 cites W2462159806 @default.
• W4309551491 cites W2531672842 @default.
• W4309551491 cites W2583926287 @default.
• W4309551491 cites W260187207 @default.
• W4309551491 cites W2609731092 @default.
• W4309551491 cites W2766740763 @default.
• W4309551491 cites W2790605163 @default.
• W4309551491 cites W2799273224 @default.
• W4309551491 cites W2802778607 @default.
• W4309551491 cites W2807319183 @default.
• W4309551491 cites W2883889243 @default.
• W4309551491 cites W2944592785 @default.
• W4309551491 cites W3022289102 @default.
• W4309551491 cites W3096091495 @default.
• W4309551491 cites W3098218729 @default.
• W4309551491 cites W3107455715 @default.
• W4309551491 cites W3118972515 @default.
• W4309551491 cites W4283310825 @default.
• W4309551491 doi "https://doi.org/10.1016/j.jpain.2022.11.006" @default.
• W4309551491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36417966" @default.
• W4309551491 hasPublicationYear "2023" @default.
• W4309551491 type Work @default.
• W4309551491 citedByCount "3" @default.
• W4309551491 countsByYear W43095514912022 @default.
• W4309551491 countsByYear W43095514912023 @default.
• W4309551491 crossrefType "journal-article" @default.
• W4309551491 hasAuthorship W4309551491A5001243278 @default.
• W4309551491 hasAuthorship W4309551491A5012818050 @default.
• W4309551491 hasAuthorship W4309551491A5024187988 @default.
• W4309551491 hasAuthorship W4309551491A5035762137 @default.
• W4309551491 hasAuthorship W4309551491A5037411659 @default.
• W4309551491 hasAuthorship W4309551491A5040294572 @default.
• W4309551491 hasAuthorship W4309551491A5060694758 @default.
• W4309551491 hasAuthorship W4309551491A5077315361 @default.
• W4309551491 hasAuthorship W4309551491A5079356211 @default.
• W4309551491 hasBestOaLocation W43095514911 @default.
• W4309551491 hasConcept C126322002 @default.
• W4309551491 hasConcept C150903083 @default.
• W4309551491 hasConcept C15490471 @default.
• W4309551491 hasConcept C170493617 @default.
• W4309551491 hasConcept C207001950 @default.
• W4309551491 hasConcept C26291073 @default.
• W4309551491 hasConcept C2776885963 @default.

• next